Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki,...
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of MAB.WA is 10.0 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell